Renal Cell Cancer Treatment–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (12/03/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage IV and Recurrent Renal Cell Cancer

Added text to state that the benefit of initial cytoreductive nephrectomy surgery has not been evaluated in an era with available antiangiogenic and other targeted therapies.

Added Cabozantinib as a new subsection.

Added mTOR inhibitors as a new subsection.

Added Immunotherapy as a new subsection.

Revised text about single or combination therapies to list first-line therapies. Added 2013 Motzer et al. as reference 19 and 2014 Escudier et al. as reference 20.

Revised text about single or combination therapies to list second-line therapies and added nivolumab (cited 2015 Motzer et al. as reference 26) and cabozantinib (cited Choueiri et al. as reference 21); also cited 2007 Escudier et al. as reference 42.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Stage IV and Recurrent Renal Cell Cancer

Next section >
About This PDQ Summary